98%
921
2 minutes
20
Objective: To examine the association of systolic blood pressure (SBP) and cardiovascular risk in normotensive adults.
Patients And Methods: This study analyzed data from 7 prospective cohorts between September 29, 1948, and December 31, 2018. Complete information on history of hypertension and baseline blood pressure measurements were required for inclusion. We excluded individuals younger than 18 years old, those with a history of hypertension, and patients with baseline SBP measurements of less than 90 mm Hg or 140 mm Hg or higher. Cox proportional hazards regression and restricted cubic spline models were used to evaluate the hazards of cardiovascular outcomes.
Results: A total of 31,033 participants were included. The mean ± SD age was 45.3±14.8 years, 16,693 of the participants (53.8%) were female, and the mean ± SD SBP was 115.8±11.7. Over a median follow-up of 23.5 years, 7005 cardiovascular events occurred. Compared with those who had SBP levels of 90 to 99 mm Hg, participants with SBP levels of 100 to 109, 110 to 119, 120 to 129, and 130 to 139 mm Hg experienced 23% (hazard ratio [HR], 1.23; 95% CI, 1.07 to 1.42), 53% (HR, 1.53; 95% CI, 1.33 to 1.76), 87% (HR, 1.87; 95% CI, 1.62 to 2.16), and 117% (HR, 2.17; 95% CI, 1.87 to 2.52) increased risks of cardiovascular events, respectively. Compared with follow-up SBP of 90 to 99 mm Hg, the HRs for cardiovascular events were 1.25 (95% CI, 1.02 to 1.54), 1.93 (95% CI, 1.58 to 2.34), 2.55 (95% CI, 2.09 to 3.10), and 3.39 (95% CI, 2.78 to 4.14), respectively, for follow-up SBP levels of 100 to 109, 110 to 119, 120 to 129, and 130 to 139 mm Hg.
Conclusion: In adults without hypertension, there is a stepwise increase in risk of cardiovascular events, with increasing SBP starting at levels as low as 90 mm Hg.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.mayocp.2022.10.011 | DOI Listing |
Circ Cardiovasc Qual Outcomes
September 2025
Cardiology Department, Cardiac Intensive Care Unit, Hospital Vall Hebron, VHIR SIM CES Research Group, Universitat Autónoma de Barcelona, Spain (J.B.-R.).
Background: Effective risk communication is essential in managing cardiovascular disease, the leading cause of global mortality. Clear communication between patients and physicians supports informed decision-making, yet comprehension gaps persist. We aimed to assess the quality of risk communication during hospital admissions for cardiovascular events, from patient and physician perspectives, and identify discrepancies in risk perception and associated factors.
View Article and Find Full Text PDFEur J Prev Cardiol
September 2025
Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Background And Aims: Data on cardiovascular outcomes and aortic growth in pregnant women with Turner syndrome is limited. We examine the cardiovascular and pregnancy outcomes in these women and analyze aortic growth throughout pregnancy.
Methods: The ROPAC III is a global, prospective, observational registry that enrolled pregnancies of women pre-pregnancy known with Turner syndrome from 2018 to 2023.
Eur J Heart Fail
September 2025
Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Aims: The estimated glucose disposal rate (eGDR) is a simple, non-invasive measure of insulin resistance. In this exploratory analysis of FINEARTS-HF, we evaluated whether lower eGDR, reflecting greater insulin resistance, is associated with adverse outcomes in heart failure (HF).
Methods And Results: The eGDR was calculated at baseline using waist circumference, glycated haemoglobin, and hypertension status.
Eur J Heart Fail
September 2025
Brazilian Clinical Research Institute (BCRI), São Paulo, Brazil.
Aims: The PARACHUTE-HF trial (NCT04023227) is evaluating the effect of sacubitril/valsartan compared with enalapril on a hierarchical composite of cardiovascular events (cardiovascular death, first heart failure hospitalization), and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in participants with heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy (CCC). We describe the baseline characteristics of participants in PARACHUTE-HF compared with prior HFrEF trials.
Methods And Results: PARACHUTE-HF, a multicentre, active-controlled, open-label trial, enrolled 922 participants with confirmed CCC, New York Heart Association (NYHA) functional class II-IV, and left ventricular ejection fraction (LVEF) ≤40%.
Catheter Cardiovasc Interv
September 2025
IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy.
Background: Given the divergence in recommendations regarding the relevance of inducible ischemia regarding the indication to revascularize chronic total occlusions (CTOs) among European and North American guidelines, we aim at investigating the prevalence and the prognostic impact of significant inducible ischemia in an unselected cohort of asymptomatic CTO patients, integrating collateralization status and viability assessment with stress cardiac magnetic resonance (CMR).
Methods: From a cohort of 749 patients referred to our center with a diagnosis of CTO, we retrospectively analyzed 111 asymptomatic individuals who underwent an adenosine stress CMR. The amount of inducible ischemia subtended by the CTO was calculated, as well as the presence of viable myocardium and the collateralization status.